Abstract
Two herds of extensively managed yearling Bos indicus and Bos indicus × Bos taurus heifers (n = 169) were assigned to one of three estrus synchronization treatment groups. The treatments consisted of 1) two injections of the prostaglandin (F 2α) analogue, luprostiol (7.5 mg), given 12-d apart; 2) insertion of an intravaginal progesterone-releasing device (CIDR-B), followed by 400 IU i.m. pregnant mare serum gonadotrophin (PMSG) and 7.5 mg luprostinol at CIDR-B removal or 3) subcutaneous progestagen implant (SMB) for 10-d, followed by 400 IU i.m. and 7.5 mg i.m. luprostiol at implant removal. A dual tail paint-raddle system was used to evaluate response to treatment. Each treatment group was inseminated according to the manufacturer's recommendations for fixed-time artificial insemination (A.I.; luprostiol, 72h after the second injection, SMB and CIDR-B 48h after implant/device removal). The overall 51-d pregnancy rates for the three treatments were 18.6% (luprostiol), 48.8% (CIDR-B), and 53.3% (SMB). There were significant differences in the pregnancy rate between CIDR-B and luprostiol (P = 0.004) and between SMB and luprostiol (P =< 0.0001), but there was no difference in pregnancy rate between CIDR-B and SMB treatment.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
